Intravesical chemotherapy for carcinoma in situ of the urinary bladder: 5 years later.
46 patients with carcinoma in situ of the urinary bladder were treated with intracavitary chemotherapy. The mean follow-up was 33 months. Tumor remission, defined by negative cytology and no evidence of TIS or severe dysplasia on biopsy, was achieved in 78%. There were 6 deaths, but only 1 was due to bladder cancer. 22 patients were followed after the termination of the planned treatment protocol. Recurrence of carcinoma in situ or development of a superficial bladder cancer was observed in 10 (45%). Bladder biopsies performed at the end of treatment were of no predictive value with regard to tumor recurrence. Tumor remission was achieved in all patients who received repeated intracavitary chemotherapy.
D000328:Adult; D000368:Aged; D002278:Carcinoma in Situ / Q000188:drug therapy*; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D008937:Mitomycins; D016685:Mitomycin; D004317:Doxorubicin